首页 > 最新文献

JAMA Health Forum最新文献

英文 中文
Gaps in US Psychedelic Policy and How to Close Them. 美国迷幻药政策的差距以及如何缩小差距。
IF 11.3 Q1 HEALTH CARE SCIENCES & SERVICES Pub Date : 2025-11-07 DOI: 10.1001/jamahealthforum.2025.4928
Caleigh Propes, Katherine Cheung, Matthew D Eisenberg, David Yaden
{"title":"Gaps in US Psychedelic Policy and How to Close Them.","authors":"Caleigh Propes, Katherine Cheung, Matthew D Eisenberg, David Yaden","doi":"10.1001/jamahealthforum.2025.4928","DOIUrl":"https://doi.org/10.1001/jamahealthforum.2025.4928","url":null,"abstract":"","PeriodicalId":53180,"journal":{"name":"JAMA Health Forum","volume":"6 11","pages":"e254928"},"PeriodicalIF":11.3,"publicationDate":"2025-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145460700","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Establishing Community Networks to Support Routine Vaccination. 建立社区网络以支持常规疫苗接种。
IF 11.3 Q1 HEALTH CARE SCIENCES & SERVICES Pub Date : 2025-11-07 DOI: 10.1001/jamahealthforum.2025.6266
Vanya Jones, Joshua M Sharfstein
{"title":"Establishing Community Networks to Support Routine Vaccination.","authors":"Vanya Jones, Joshua M Sharfstein","doi":"10.1001/jamahealthforum.2025.6266","DOIUrl":"https://doi.org/10.1001/jamahealthforum.2025.6266","url":null,"abstract":"","PeriodicalId":53180,"journal":{"name":"JAMA Health Forum","volume":"6 11","pages":"e256266"},"PeriodicalIF":11.3,"publicationDate":"2025-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145566292","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Racial Disparities in Premature Mortality and Unrealized Medicare Benefits Across US States. 美国各州过早死亡率和未实现医疗保险福利的种族差异。
IF 11.3 Q1 HEALTH CARE SCIENCES & SERVICES Pub Date : 2025-11-07 DOI: 10.1001/jamahealthforum.2025.4916
Irene Papanicolas, Maecey Niksch, Jinru Wei, Reginald D Williams, Jose F Figueroa
{"title":"Racial Disparities in Premature Mortality and Unrealized Medicare Benefits Across US States.","authors":"Irene Papanicolas, Maecey Niksch, Jinru Wei, Reginald D Williams, Jose F Figueroa","doi":"10.1001/jamahealthforum.2025.4916","DOIUrl":"10.1001/jamahealthforum.2025.4916","url":null,"abstract":"","PeriodicalId":53180,"journal":{"name":"JAMA Health Forum","volume":"6 11","pages":"e254916"},"PeriodicalIF":11.3,"publicationDate":"2025-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12595528/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145460783","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hospital Acquisition Costs for Breakthrough-Designated Devices Awarded Supplemental Medicare Reimbursement. 获得医疗保险补充报销的突破性指定设备的医院购置费用。
IF 11.3 Q1 HEALTH CARE SCIENCES & SERVICES Pub Date : 2025-11-07 DOI: 10.1001/jamahealthforum.2025.5183
Osman Moneer, Kushal T Kadakia, Sanket S Dhruva, Joseph S Ross, Leah M Roth, James F Burke, Vinay K Rathi
{"title":"Hospital Acquisition Costs for Breakthrough-Designated Devices Awarded Supplemental Medicare Reimbursement.","authors":"Osman Moneer, Kushal T Kadakia, Sanket S Dhruva, Joseph S Ross, Leah M Roth, James F Burke, Vinay K Rathi","doi":"10.1001/jamahealthforum.2025.5183","DOIUrl":"10.1001/jamahealthforum.2025.5183","url":null,"abstract":"","PeriodicalId":53180,"journal":{"name":"JAMA Health Forum","volume":"6 11","pages":"e255183"},"PeriodicalIF":11.3,"publicationDate":"2025-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12658659/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145607291","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
US Laws Restricting Medical Care for Transgender Minors: Statutory Inconsistencies Involving Intersex and Other Individuals. 限制变性未成年人医疗服务的美国法律:涉及双性人和其他个体的法律不一致。
IF 11.3 Q1 HEALTH CARE SCIENCES & SERVICES Pub Date : 2025-11-07 DOI: 10.1001/jamahealthforum.2025.4157
Sara A Mar, Brian D Earp, Gnendy Indig, Meredithe McNamara, Elizabeth R Boskey, Katharine B Dalke, Elizabeth Dietz, Morgan Carpenter, Cynthia Kraus, Erika Lorshbough, Quinnehtukqut McLamore, Kimberly Zieselman, Hannah C Wenger

Importance: Since 2021, there have been growing calls in the US to prohibit gender-affirming medical care (GAMC) for transgender and gender-diverse (TGD) minors (ie, <18 years). Supporters of these bans have argued the restrictions are necessary to protect TGD minors from potentially risky or unproven medical interventions; however, the same bans include exceptions for similar procedures when performed on presumptively non-TGD minors: primarily, infants and children with variations in sex characteristics, or intersex traits.

Objective: To comprehensively describe US legislation seeking to prohibit GAMC for TGD individuals and determine the extent to which such legislation contains exceptions for similar interventions performed on presumptively non-TGD minors.

Evidence review: All US jurisdictions with statutes restricting GAMC across 4 full legislative sessions (January 1, 2021, to December 31, 2024) were searched. For each statute, the authors identified descriptions of sex, gender, and GAMC; restricted health care services; stated purpose(s) for which services are restricted; exceptions to restrictions; and penalties for statutory violations.

Findings: All US states with legislation restricting voluntarily sought TGD-related health care contain statutory exceptions that allow for physically comparable, but typically nonvoluntary interventions to "normalize" the benign bodily attributes of children with intersex traits. Some statutes also explicitly permit medically unnecessary procedures like penile circumcision on presumptively non-TGD minors.

Conclusions and relevance: Inconsistent statutory rules appear to be applied to TGD and presumptively non-TGD minors. Furthermore, these findings suggest such rules are shaped by definitions of sex and gender that conflict with current scientific understanding. Sound health policy ought to afford equal access to health care services affecting sexual anatomy, without discrimination based on sex traits or gender.

重要性:自2021年以来,美国越来越多的人呼吁禁止对跨性别和性别多样化(TGD)未成年人进行性别肯定医疗(GAMC)(即,目的:全面描述美国试图禁止对TGD个人进行性别肯定医疗(GAMC)的立法,并确定该立法在多大程度上包含对推定为非TGD未成年人进行类似干预的例外情况。证据审查:所有美国司法管辖区的法规限制GAMC在四个完整的立法会议(2021年1月1日至2024年12月31日)进行了搜索。对于每个法规,作者确定了性别,性别和GAMC的描述;保健服务受限;限制提供服务的明确目的;限制的例外情况;以及对违法行为的处罚。研究结果:美国所有立法限制自愿寻求tgd相关医疗保健的州都有法定例外,允许身体上可比较的,但通常是非自愿的干预措施,以使具有双性人特征的儿童的良性身体特征“正常化”。一些法规还明确允许对推定为非tgd的未成年人进行阴茎包皮环切等医学上不必要的手术。结论和相关性:似乎不一致的法定规则适用于TGD和假定的非TGD未成年人。此外,这些发现表明,这些规则是由与当前科学理解相冲突的性和性别定义形成的。健全的卫生政策应使人们有平等的机会获得影响性解剖的保健服务,不存在基于性特征或性别的歧视。
{"title":"US Laws Restricting Medical Care for Transgender Minors: Statutory Inconsistencies Involving Intersex and Other Individuals.","authors":"Sara A Mar, Brian D Earp, Gnendy Indig, Meredithe McNamara, Elizabeth R Boskey, Katharine B Dalke, Elizabeth Dietz, Morgan Carpenter, Cynthia Kraus, Erika Lorshbough, Quinnehtukqut McLamore, Kimberly Zieselman, Hannah C Wenger","doi":"10.1001/jamahealthforum.2025.4157","DOIUrl":"https://doi.org/10.1001/jamahealthforum.2025.4157","url":null,"abstract":"<p><strong>Importance: </strong>Since 2021, there have been growing calls in the US to prohibit gender-affirming medical care (GAMC) for transgender and gender-diverse (TGD) minors (ie, <18 years). Supporters of these bans have argued the restrictions are necessary to protect TGD minors from potentially risky or unproven medical interventions; however, the same bans include exceptions for similar procedures when performed on presumptively non-TGD minors: primarily, infants and children with variations in sex characteristics, or intersex traits.</p><p><strong>Objective: </strong>To comprehensively describe US legislation seeking to prohibit GAMC for TGD individuals and determine the extent to which such legislation contains exceptions for similar interventions performed on presumptively non-TGD minors.</p><p><strong>Evidence review: </strong>All US jurisdictions with statutes restricting GAMC across 4 full legislative sessions (January 1, 2021, to December 31, 2024) were searched. For each statute, the authors identified descriptions of sex, gender, and GAMC; restricted health care services; stated purpose(s) for which services are restricted; exceptions to restrictions; and penalties for statutory violations.</p><p><strong>Findings: </strong>All US states with legislation restricting voluntarily sought TGD-related health care contain statutory exceptions that allow for physically comparable, but typically nonvoluntary interventions to \"normalize\" the benign bodily attributes of children with intersex traits. Some statutes also explicitly permit medically unnecessary procedures like penile circumcision on presumptively non-TGD minors.</p><p><strong>Conclusions and relevance: </strong>Inconsistent statutory rules appear to be applied to TGD and presumptively non-TGD minors. Furthermore, these findings suggest such rules are shaped by definitions of sex and gender that conflict with current scientific understanding. Sound health policy ought to afford equal access to health care services affecting sexual anatomy, without discrimination based on sex traits or gender.</p>","PeriodicalId":53180,"journal":{"name":"JAMA Health Forum","volume":"6 11","pages":"e254157"},"PeriodicalIF":11.3,"publicationDate":"2025-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145515021","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Adoption of Artificial Intelligence in the Health Care Sector. 人工智能在医疗保健领域的应用。
IF 11.3 Q1 HEALTH CARE SCIENCES & SERVICES Pub Date : 2025-11-07 DOI: 10.1001/jamahealthforum.2025.5029
Thuy D Nguyen, Christopher M Whaley, Kosali Simon, Neil Mehta, Hao Yu, Ryan K McBain, Ateev Mehrotra, Jonathan H Cantor
{"title":"Adoption of Artificial Intelligence in the Health Care Sector.","authors":"Thuy D Nguyen, Christopher M Whaley, Kosali Simon, Neil Mehta, Hao Yu, Ryan K McBain, Ateev Mehrotra, Jonathan H Cantor","doi":"10.1001/jamahealthforum.2025.5029","DOIUrl":"10.1001/jamahealthforum.2025.5029","url":null,"abstract":"","PeriodicalId":53180,"journal":{"name":"JAMA Health Forum","volume":"6 11","pages":"e255029"},"PeriodicalIF":11.3,"publicationDate":"2025-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12639477/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145566249","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Trends in Methadone Use for Pain and Opioid Use Disorder Among Medicaid Enrollees. 美沙酮用于治疗疼痛和阿片类药物使用障碍的趋势
IF 11.3 Q1 HEALTH CARE SCIENCES & SERVICES Pub Date : 2025-11-07 DOI: 10.1001/jamahealthforum.2025.5023
Yu-Chia Sam Hsu, Ashish P Thakrar, Charles E Leonard, Margaret Lowenstein, Colleen M Brensinger, Warren B Bilker, Kacie F Bogar, Sean Hennessy
{"title":"Trends in Methadone Use for Pain and Opioid Use Disorder Among Medicaid Enrollees.","authors":"Yu-Chia Sam Hsu, Ashish P Thakrar, Charles E Leonard, Margaret Lowenstein, Colleen M Brensinger, Warren B Bilker, Kacie F Bogar, Sean Hennessy","doi":"10.1001/jamahealthforum.2025.5023","DOIUrl":"10.1001/jamahealthforum.2025.5023","url":null,"abstract":"","PeriodicalId":53180,"journal":{"name":"JAMA Health Forum","volume":"6 11","pages":"e255023"},"PeriodicalIF":11.3,"publicationDate":"2025-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12639476/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145566377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Adherence, Switches, and Drug Spending After Angiotensin Receptor Blocker Recalls and Shortages. 血管紧张素受体阻滞剂召回和短缺后的依从性、开关和药物支出。
IF 11.3 Q1 HEALTH CARE SCIENCES & SERVICES Pub Date : 2025-11-07 DOI: 10.1001/jamahealthforum.2025.4078
Katherine Callaway Kim, Eric T Roberts, Julie M Donohue, Lindsay M Sabik, Chester B Good, Joshua W Devine, Mina Tadrous, Katie J Suda
<p><strong>Importance: </strong>Angiotensin II receptor blockers (ARBs) are common treatments for hypertension, heart failure, and chronic kidney disease. From 2018 to 2019, hundreds of valsartan, losartan, and irbesartan products were recalled due to ingredient impurities.</p><p><strong>Objective: </strong>To estimate the impact of the 2018 to 2019 ARB shortages on medication adherence, switches to alternatives, and associated drug spending up to 18 months.</p><p><strong>Design, setting, and participants: </strong>This longitudinal cohort study with a difference-in-differences (DiD) analysis used pharmacy claims data from IQVIA's all-payer Formulary Impact Analyzer dataset from July 2017 to January 2020, comprising prerecall users of valsartan, irbesartan, and losartan vs similar nonrecalled medications (other ARBs, angiotensin-converting enzyme inhibitors [ACEIs]). Analyses were conducted from November 2023 to October 2025.</p><p><strong>Exposures: </strong>Use of the recalled drugs (valsartan, irbesartan, and losartan) at baseline vs comparison antihypertensives (nonrecalled ARBs, ACEIs).</p><p><strong>Main outcomes and measures: </strong>Mean proportion of days covered for ARBs and ACEIs, switches to alternatives, medication gaps of 30 or more days, and associated drug spending (insurer and patient out-of-pocket costs).</p><p><strong>Results: </strong>For 13.8 million ARB users (median [IQR] age in 2018, 66 [56-74] years; 54.8% female) vs 23.4 million comparison drug users (median [IQR] age in 2018, 62 [54-72] years; 46.0% female), mean proportion of days covered changed by 0.55 percentage points (pp; 95% CI, 0.34-0.76 pp) within 18 months. Relative changes in gaps of 30 or more days, insurer drug spending, and patient out-of-pocket drug spending changed by less than 5% (relative changes of -2.5%, 0.6%, and 3.7%, respectively). ARB users experienced an increase in medication switches in the 90 days after the valsartan recall (DiD estimate: 8.46 pp; 95% CI, 8.30-8.63 pp; 229.0% relative increase). Smaller increases in switching occurred after the first irbesartan and first losartan recalls (DiD estimate: 1.20 pp; 95% CI, 1.12-1.27 pp; 32.4% relative increase). The proportion of individuals switching was greater among those with Medicare (DiD estimate: 9.49 pp; 95% CI, 9.28-9.72 pp; 256.8% relative increase) or third-party insurance (DiD estimate: 7.81 pp; 95% CI, 7.57-8.04 pp; 210.8% relative increase) vs Medicaid fee-for-service insurance (DiD estimate: 2.54 pp; 95% CI, 2.31-2.77 pp; 43.1% relative increase) or among customers paying with cash (DiD estimate: 3.42 pp; 95% CI, 3.22-3.61 pp; 87.1% relative increase).</p><p><strong>Conclusions and relevance: </strong>This cohort study shows that access to alternatives may have mitigated gaps in treatment during the 2018 to 2019 ARB recalls and drug shortages. Potential disparate impacts among certain subgroups highlight the need for policies to mitigate financial and other systematic access barri
重要性:血管紧张素II受体阻滞剂(ARBs)是高血压、心力衰竭和慢性肾脏疾病的常用治疗方法。2018年至2019年,数百种缬沙坦、氯沙坦和厄贝沙坦产品因成分杂质被召回。目的:评估2018 - 2019年ARB短缺对长达18个月的药物依从性、替代药物转换和相关药物支出的影响。设计、环境和参与者:这项纵向队列研究采用了差异中差异(DiD)分析,使用了2017年7月至2020年1月IQVIA的全付款人处方影响分析仪数据集的药房索赔数据,包括缬沙坦、伊贝沙坦和氯沙坦的召回前使用者与类似的未召回药物(其他arb、血管紧张素转换酶抑制剂[ACEIs])。分析时间为2023年11月至2025年10月。暴露:基线时召回药物(缬沙坦、厄贝沙坦和氯沙坦)与对照抗高血压药物(未召回的arb、acei)的使用情况。主要结果和措施:arb和acei的平均覆盖天数比例,替代方案的切换,30天或更长时间的用药缺口,以及相关的药物支出(保险公司和患者自付费用)。结果:1380万ARB使用者(2018年[IQR]年龄中位数为66[56-74]岁,女性占54.8%)与2340万对照药物使用者(2018年[IQR]年龄中位数为62[54-72]岁,女性占46.0%)在18个月内的平均覆盖天数比例变化了0.55个百分点(pp; 95% CI, 0.34-0.76 pp)。间隔30天及以上、保险公司药品支出和患者自付药品支出的相对变化小于5%(相对变化分别为-2.5%、0.6%和3.7%)。缬沙坦召回后90天内,ARB使用者的药物切换次数增加(DiD估计:8.46 pp; 95% CI, 8.30-8.63 pp;相对增加229.0%)。在第一次厄贝沙坦和氯沙坦召回后,切换的增加较小(DiD估计:1.20 pp; 95% CI, 1.12-1.27 pp;相对增加32.4%)。在医疗保险(DiD估计:9.49 pp; 95% CI, 9.28-9.72 pp;相对增加256.8%)或第三方保险(DiD估计:7.81 pp; 95% CI, 7.57-8.04 pp;相对增加210.8%)与医疗补助按服务收费保险(DiD估计:2.54 pp; 95% CI, 2.31-2.77 pp;相对增加43.1%)或现金支付的客户(DiD估计:3.42 pp; 95% CI, 3.22-3.61 pp;相对增加87.1%)中,个人转换的比例更大。结论和相关性:该队列研究表明,获得替代品可能缓解了2018年至2019年ARB召回和药物短缺期间的治疗差距。某些亚群体之间潜在的不同影响突出表明,需要制定政策,减轻在药物短缺期间获得卫生保健的财务和其他系统性障碍。
{"title":"Adherence, Switches, and Drug Spending After Angiotensin Receptor Blocker Recalls and Shortages.","authors":"Katherine Callaway Kim, Eric T Roberts, Julie M Donohue, Lindsay M Sabik, Chester B Good, Joshua W Devine, Mina Tadrous, Katie J Suda","doi":"10.1001/jamahealthforum.2025.4078","DOIUrl":"10.1001/jamahealthforum.2025.4078","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Importance: &lt;/strong&gt;Angiotensin II receptor blockers (ARBs) are common treatments for hypertension, heart failure, and chronic kidney disease. From 2018 to 2019, hundreds of valsartan, losartan, and irbesartan products were recalled due to ingredient impurities.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Objective: &lt;/strong&gt;To estimate the impact of the 2018 to 2019 ARB shortages on medication adherence, switches to alternatives, and associated drug spending up to 18 months.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Design, setting, and participants: &lt;/strong&gt;This longitudinal cohort study with a difference-in-differences (DiD) analysis used pharmacy claims data from IQVIA's all-payer Formulary Impact Analyzer dataset from July 2017 to January 2020, comprising prerecall users of valsartan, irbesartan, and losartan vs similar nonrecalled medications (other ARBs, angiotensin-converting enzyme inhibitors [ACEIs]). Analyses were conducted from November 2023 to October 2025.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Exposures: &lt;/strong&gt;Use of the recalled drugs (valsartan, irbesartan, and losartan) at baseline vs comparison antihypertensives (nonrecalled ARBs, ACEIs).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Main outcomes and measures: &lt;/strong&gt;Mean proportion of days covered for ARBs and ACEIs, switches to alternatives, medication gaps of 30 or more days, and associated drug spending (insurer and patient out-of-pocket costs).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;For 13.8 million ARB users (median [IQR] age in 2018, 66 [56-74] years; 54.8% female) vs 23.4 million comparison drug users (median [IQR] age in 2018, 62 [54-72] years; 46.0% female), mean proportion of days covered changed by 0.55 percentage points (pp; 95% CI, 0.34-0.76 pp) within 18 months. Relative changes in gaps of 30 or more days, insurer drug spending, and patient out-of-pocket drug spending changed by less than 5% (relative changes of -2.5%, 0.6%, and 3.7%, respectively). ARB users experienced an increase in medication switches in the 90 days after the valsartan recall (DiD estimate: 8.46 pp; 95% CI, 8.30-8.63 pp; 229.0% relative increase). Smaller increases in switching occurred after the first irbesartan and first losartan recalls (DiD estimate: 1.20 pp; 95% CI, 1.12-1.27 pp; 32.4% relative increase). The proportion of individuals switching was greater among those with Medicare (DiD estimate: 9.49 pp; 95% CI, 9.28-9.72 pp; 256.8% relative increase) or third-party insurance (DiD estimate: 7.81 pp; 95% CI, 7.57-8.04 pp; 210.8% relative increase) vs Medicaid fee-for-service insurance (DiD estimate: 2.54 pp; 95% CI, 2.31-2.77 pp; 43.1% relative increase) or among customers paying with cash (DiD estimate: 3.42 pp; 95% CI, 3.22-3.61 pp; 87.1% relative increase).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions and relevance: &lt;/strong&gt;This cohort study shows that access to alternatives may have mitigated gaps in treatment during the 2018 to 2019 ARB recalls and drug shortages. Potential disparate impacts among certain subgroups highlight the need for policies to mitigate financial and other systematic access barri","PeriodicalId":53180,"journal":{"name":"JAMA Health Forum","volume":"6 11","pages":"e254078"},"PeriodicalIF":11.3,"publicationDate":"2025-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12658656/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145607281","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Study Designs and Methods for Health Policy and Health Services Research: A Look Back, A Look Ahead. 卫生政策和卫生服务研究的研究设计和方法:回顾,展望。
IF 11.3 Q1 HEALTH CARE SCIENCES & SERVICES Pub Date : 2025-11-07 DOI: 10.1001/jamahealthforum.2025.5191
Austin S Kilaru, Julie M Donohue, Sandro Galea
{"title":"Study Designs and Methods for Health Policy and Health Services Research: A Look Back, A Look Ahead.","authors":"Austin S Kilaru, Julie M Donohue, Sandro Galea","doi":"10.1001/jamahealthforum.2025.5191","DOIUrl":"https://doi.org/10.1001/jamahealthforum.2025.5191","url":null,"abstract":"","PeriodicalId":53180,"journal":{"name":"JAMA Health Forum","volume":"6 11","pages":"e255191"},"PeriodicalIF":11.3,"publicationDate":"2025-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145566302","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Enduring Impact of the National Institute of Nursing Research and Why We Still Need It. 国家护理研究所的持久影响以及为什么我们仍然需要它。
IF 11.3 Q1 HEALTH CARE SCIENCES & SERVICES Pub Date : 2025-11-07 DOI: 10.1001/jamahealthforum.2025.5188
Mary D Naylor, Martha A Q Curley, Connie M Ulrich
{"title":"The Enduring Impact of the National Institute of Nursing Research and Why We Still Need It.","authors":"Mary D Naylor, Martha A Q Curley, Connie M Ulrich","doi":"10.1001/jamahealthforum.2025.5188","DOIUrl":"https://doi.org/10.1001/jamahealthforum.2025.5188","url":null,"abstract":"","PeriodicalId":53180,"journal":{"name":"JAMA Health Forum","volume":"6 11","pages":"e255188"},"PeriodicalIF":11.3,"publicationDate":"2025-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145566341","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
JAMA Health Forum
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1